Biden Backs Waiver of Patent for COVID-19 Vaccines, Pharma Companies Don’t Like It That Much?

Be the First to Comment Read

Biden Backs Waiver of Patent for COVID-19 Vaccines, Pharma Companies Don’t Like It That Much?

 Biden Backs Waiver of Patent for COVID-19 Vaccines, Pharma Companies Don’t Like It That Much?
Image source: MBLifestyle, Shutterstock

In a big development, Joe Biden, the US President, has supported the waiver of intellectual property rights for COVID-19 vaccines. This would enable the poor countries to manaufacture those vaccines in their territories.

While some called it bowing to pressure from India and South Africa, who had called for an IP waiver on vaccines, the World Health Organisation lauded the decision and called it momentous in the fight against the century’s biggest crisis.

WHO Lauds The Decision

Tedros Adhanom Ghebreyesus, The Director General of the World Health Organisation (WHO), called Biden Administration’s decision a powerful example of the US leadership in addressing global health issues.

Image Source: Copyright © 2021 Kalkine Media Pty Ltd

He added that the US’ decision to support temporary waiving of IP for COVID-19 vaccines shows the high moral standing of the leadership of the US.

The US Trade Representative at the World Trade Organisation, Katherine Tai, said that because coronavirus pandemic was a global crisis and produced extraordinary circumstances, it required an extraordinary response.

It is being believed that the US has agreed only partially to the Indian and South African plan. It covers only vaccines and not therapeutics. Given the consensus-based approach in the WTO, it might take some time to happen. However, at the WTO, Katherine Tai also said that the US administrations strongly believed in intellectual property protections but in view of COVID-19 situation, the US was supporting the waiver for the time being. She also said that the US would actively participate in the WTO negotiations and see that it happened.

Pharmaceutical Companies Not happy

In the meantime, the pharmaceutical companies are not happy with the US’ decision. They are saying that this is not the right answer to the global health problem. Geneva-based International Federation of Pharmaceutical Manufactures and Associations said that waiving patents of the coronavirus vaccines would not necessarily boost the production. What is needed is a correction in the supply-chain disruptions and logistics.  They even went to the extent of saying that that move of Biden had set a dangerous precedent.

Shares of main vaccine makers like Moderna Inc and Novavax Inc dropped several points in regular trade, although Pfizer Inc stock fell only marginally.

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK